Additionally, the 36-month beta value for MDGL is -0.43. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MDGL is 17.53M and currently, short sellers hold a 29.83% ratio of that float. The average trading volume of MDGL on June 19, 2024 was 494.13K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MDGL) stock’s latest price update
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)’s stock price has dropped by -0.26 in relation to previous closing price of 276.72. Nevertheless, the company has seen a loss of -5.47% in its stock price over the last five trading days. fool.com reported 2024-06-16 that Madrigal Pharmaceuticals is the only company with an approved drug for MASH. Eli Lilly’s latest clinical trial data shows that its candidate may perform even better.
MDGL’s Market Performance
Madrigal Pharmaceuticals Inc (MDGL) has experienced a -5.47% fall in stock performance for the past week, with a 25.42% rise in the past month, and a 3.89% rise in the past quarter. The volatility ratio for the week is 4.06%, and the volatility levels for the past 30 days are at 6.24% for MDGL. The simple moving average for the past 20 days is 11.36% for MDGL’s stock, with a 32.22% simple moving average for the past 200 days.
Analysts’ Opinion of MDGL
Many brokerage firms have already submitted their reports for MDGL stocks, with Wolfe Research repeating the rating for MDGL by listing it as a “Outperform.” The predicted price for MDGL in the upcoming period, according to Wolfe Research is $382 based on the research report published on June 11, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see MDGL reach a price target of $150. The rating they have provided for MDGL stocks is “Underperform” according to the report published on April 22nd, 2024.
B. Riley Securities gave a rating of “Neutral” to MDGL, setting the target price at $270 in the report published on March 15th of the current year.
MDGL Trading at 19.60% from the 50-Day Moving Average
After a stumble in the market that brought MDGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.99% of loss for the given period.
Volatility was left at 6.24%, however, over the last 30 days, the volatility rate increased by 4.06%, as shares surge +18.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.01% upper at present.
During the last 5 trading sessions, MDGL fell by -5.47%, which changed the moving average for the period of 200-days by +53.34% in comparison to the 20-day moving average, which settled at $250.05. In addition, Madrigal Pharmaceuticals Inc saw 19.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MDGL starting from Waltermire Robert E., who sale 1,900 shares at the price of $280.00 back on Jun 14 ’24. After this action, Waltermire Robert E. now owns 5,500 shares of Madrigal Pharmaceuticals Inc, valued at $532,000 using the latest closing price.
Waltermire Robert E., the Senior VP, Chief Pharma Dev. of Madrigal Pharmaceuticals Inc, sale 2,000 shares at $285.00 during a trade that took place back on Jun 12 ’24, which means that Waltermire Robert E. is holding 5,500 shares at $570,000 based on the most recent closing price.
Stock Fundamentals for MDGL
The total capital return value is set at -0.47. Equity return is now at value -88.78, with -62.81 for asset returns.
Based on Madrigal Pharmaceuticals Inc (MDGL), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -3.34. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is -63.03.
Currently, EBITDA for the company is -379.97 million with net debt to EBITDA at 1.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.39.
Conclusion
In conclusion, Madrigal Pharmaceuticals Inc (MDGL) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
